CM326 for moderate to severe COPD
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 85 years old.
- Your COPD diagnosis must be at least 12 months old.
- In the past year, you must have had at least 2 moderate COPD flare-ups or 1 severe flare-up that needed hospitalization.
- You must be a current or former smoker (or exposed to biomass smoke) for at least 10 years.
- Your lung function tests must show a certain level of obstruction (FEV1/FVC < 0.70 and FEV1 between 20% and 80% of normal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a structured care program for COPD can lower how often your symptoms flare up. It may help by improving everyday management and preventing future worsening.
This study tests a new injectable medicine called CM310 for people with moderate to severe COPD who have chronic bronchitis and frequent flare-ups, despite using standard inhalers. It aims to see if CM310 can reduce flare-ups and improve breathing by targeting a specific type of inflammation.
This study tests a new medication called CM512 for people with moderate-to-severe COPD who still have flare-ups despite using their regular inhalers. It aims to see if adding this treatment can reduce flare-ups and improve quality of life.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This study tests CM310 to see if it can improve asthma in people with moderate to severe asthma who are still having uncontrolled symptoms and severe flare-ups despite regular inhaler treatment. You may be eligible if your lung function and asthma control tests fit the study limits and you’ve had a recent severe exacerbation.
This trial tests a new medicine, Hemay005, in adults with moderate to severe COPD who also have a chronic cough with mucus. It looks at how the drug affects certain markers in the body related to the disease.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.